GCI has received consultancy or advisory fees from Novartis, Kura Oncology and NuProbe and has received research funds from Celgene, Novartis, Kura Oncology, Syndax Pharmaceuticals, Merck, Cullinan Oncology and NuProbe. IA has received consultancy or advisory fees from Amgen, Pfizer, Jazz, AbbVie and Agios, research funding from AbbVie and Macrogenics, and honoraria from Amgen, Pfizer, Jazz, AbbVie and Agios. JDP has an advisory role with Incyte and RiverVest Venture Partners, has served as a board member or advisory committee member with RiverVest Venture Partners, Magenta, hC Bioscience, Inc. and WUGEN, has received research funding from NeoImmune Tech, Macrogenics, Incyte, Bioline Rx and WUGEN and holds patents or patents pending for UCART7 for the treatment of T-ALL, VLA-4 inhibitors for stem cell mobilization and NT-I7 for the expansion of CART. RS has served on the AbbVie Steering Committee and advisory boards for AbbVie, AvenCell, CTI Pharma, Kura One, Genentech, Actinium, Arog, BMS, Boston Pharmaceuticals, GSK, Janssen, Jazz, Novartis, Syros, Takeda, Elevate Bio , Syndax Pharmaceuticals, Gemoab, BerGenBio, Foghorn Tera, Aprea, Innate, Actinium and OncoNova; served as DSMB for Aptevo, Epizyme, Takeda and Syntrix/ACI Clinical; on the BerGenBio discussion group; and on GSK’s AML Expert Council and Jazz Pharmaceuticals’ Grand Rounds. MA has served on the advisory boards of Kite Pharma and Syndax Pharmaceuticals. MJT has an advisory role with AbbVie and CVS, has an expert testimony role with Apotex, and has received research funding from AbbVie, Gilead Sciences, Janssen, Merck, Pharmacyclics, Syndax Pharmaceuticals, TG Therapeutics and Tolero. MRP held a senior position at ION Pharma; received honoraria from Pfizer, Pharmacyclics, Bayer, Janssen Oncology, Genentech and Adaptive Biotechnologies; has a consulting or advisory role with Pharmacyclics/Janssen and Pfizer/EMD Serono; served on the Speakers Bureau of Exelixis, Genentech/Roche, Taiho Pharmaceutical and Celgene; and has received research funding from Acerta Pharma, ADC Therapeutics, Agenus, Aileron Therapeutics, AstraZeneca, BioNTech AG, Boehringer Ingelheim, Celgene, Checkpoint Therapeutics, CicloMed, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo, Lilly, EMD Serono, Evelo Therapeutics, FORMA Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Janssen, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics, Pfizer, Placon, Portola Pharmaceuticals, Prelude Therapeutics, Ribon Therapeutics, Seven and Eight Biopharmaceuticals, Syndax Pharmaceuticals, Taiho Pharmaceutical, Takeda, Tesaro, TopAlliance BioSciences, Inc., Vigeo, ORIC, Artios, IgM Biosciences, Puretech, BioTheryX, Black Diamond Therapeutics, IgM Biosciences, NGM Biopharmaceuticals, Nurix, PureTech, Relay Therapeutics, Samumed, Silicon Therapeutics, TeneoBio, Treadwel l Therapeutics, Zymeworks, Olema, Adagene, Astellas, NGM, Accutar Biotech, TeneoBio, Novartis, Compugen, Black Diamond Therapeutics, MabSpace Biosciences, Immunogen and Blueprint Pharmaceuticals. DSD has an advisory or advisory role to Tempus, Inc. S. Shenoy has an advisory or advisory role to Artio, BMS and Takaeda. HK has received honoraria/advisory board/advisory fees from AbbVie, Amgen, Amphista, Ascentage, Astellas, Biologix, Curis, Ipsen Biopharmaceuticals, KAHR Medical, Labcorp, Novartis, Pfizer, Shenzhen Target Rx, Stemline and Takeda; and has received research funding from AbbVie, Amgen, Ascentage, BMS, Daiichi Sankyo, Immunogen, Jazz, and Novartis. SAA has received shares or other proprietary rights of Neomorph, Inc., C4 Therapeutics, Cyteir Therapeutics, Accent Therapeutics, and Mana Therapeutics; has an advisory role with Neomorph, Inc., C4 Therapeutics, Cyteir Therapeutics, Accent Therapeutics, Mana Therapeutics and Twentyeight-Seven Therapeutics; received research funding from Syndax Pharmaceuticals and Janssen; and holds patents, royalties and other intellectual property rights for MENIN inhibition in NPM1 AML: WO/2017/132398A1. GR is a former employee of Syndax Pharmaceuticals and a current employee of Boston Pharmaceuticals. RGB is an employee of Syndax Pharmaceuticals and owns stock or other property of Syndax Pharmaceuticals. MLM, PO and GMM are employees of Syndax Pharmaceuticals. MLM has an advisory or consultancy role at Nuvalent, owns patents, royalties and other intellectual property rights at Syndax Pharmaceuticals and Nuvalent, and owns stock or other property at Syndax Pharmaceuticals and Johnson & Johnson. PO has an advisory or consultancy role with Patrys and Twentyeight-Seven Therapeutics, owns patents, royalties and other intellectual property rights in Syndax Pharmaceuticals, and owns stock or other proprietary rights in Syndax Pharmaceuticals. GMM has an advisory or advisory role in Syndax Pharmaceuticals, owns patents, royalties and other intellectual property rights in Syndax Pharmaceuticals and owns stock or other proprietary rights in Syndax Pharmaceuticals. YG is an employee of Syndax Pharmaceuticals and holds stock or other interests in Syndax Pharmaceuticals and AstraZeneca. S. Smith has a consulting or advisory role with Syndax Pharmaceuticals. EMS has an advisory or consulting role with Gilead, CTI Biopharma, Epizyme, AbbVie, Pinotbio, Neoleukin Genesis, Genentech, Jazz, Novartis, Celgene, Calithera, Takeda, Janssen, BMS, Kronos, Kura, Auron, Syndax Pharmaceuticals, Servier, Agios and Remix and has received research funding from Biotheryx, Agios, Servier, Eisai, BMS, Bayer, Syndax, Syros and Loxo. BC, FP, JAP, NS and VK declare no competing interests.